<rt id="e9p4p"></rt>
產(chǎn)品介紹
Quidel Polyclonal Antiserum to Human Factor B
A311
2.0 mL
Whole Antiserum
≤ 0.1% Sodium Azide
Baboon, Horse, Dog, Cat, Rabbit, Hamster, Mouse, Rat, Guinea Pig
2°C to 8°C (≤ 30 days)
For long-term storage (> 30 days), aliquot and store at ≤ –20°C. Avoid repeated freeze-thaw.
For Research Use Only. Not for use in diagnostic procedures
Highly purified human Factor B was isolated from normal serum and used to immunize goats. The Anti-Human Factor B polyclonal antisera was tested by double-immunodiffusion, one-dimensional immunoelectrophoresis, quantitative radial immunodiffusion, and quantitative rocket immunoelectrophoresis. The antisera was determined to be monospecific for the Factor B protein.
Primarily synthesized in the liver, Factor B is a plasma protein that is unique to the alternative pathway of the Complement system. The average concentration of Factor B in human serum/plasma is approximately 200 μg/mL. Factor B present in the circulatory system is a single-chain polypeptide with a molecular weight of 93 KD. Factor B will bind to the C3b component of the complement system in the presence of Mg++ to form the C3bB complex. This complex can be activated through cleavage of the Factor B portion by Factor D, which releases the Ba fragment of Factor B while the Bb fragment of Factor B remains bound to C3b. The C3bBb complex acts as a C3 and C5 convertase due to the serine protease activity of the Bb fragment. Presence of the split products (Ba and Bb fragments of Factor B) indicate that the alternative complement pathway has been activated. Factor B, like C2 and C4 is characterized as a Class III major histocompatibility complex (MHC) antigen. The structural gene coding for this protein is located within the MHC on chromosome 6 in man, and chromosome 17 in mice
Applications of the Factor B polyclonal antisera have been evaluated by various research facilities, and include Western Blot, 1,2 IHC, 2 Immunoprecipitation, 3 and Immunofluorescence. 1,4
1、He, Y., et al. Complement Activation in Pediatric Patients with Recurrent Acute Otitis Media. Intl. J. of Pediatric Otorhinolaryngology (2013): 911-917.
2、Schwaeble, W., et al. Human Complement Factor B: Functional Properties of a Recombinant Zymogen of the Alt. Activation Pathway Convertase. Immuniobiology (1993): 221-232.
3、Matsumoto, M., et al. Abrogation of the Alt. Complement Pathway by Targeted Deletion of Murine Factor B. Proceedings of the Nat. Academy of Sciences (1997): 8720-8725
BIOLEAF熱搜 BIOLEAF試劑盒 BIOLEAF ELISA BIOLEAF試劑 BIOLEAF品牌 BIOLEAF抗體 BIOLEAF耗材 BIOLEAF小儀器
sitemap 細胞庫查詢 危險品圖標 本公司網(wǎng)站所展示銷售的產(chǎn)品僅供科研！
滬公網(wǎng)安備 31011202007338號
